Share on StockTwits

BTG plc (LON:BTG)‘s stock had its “sell” rating reaffirmed by N+1 Singer in a research note issued on Wednesday. They currently have a GBX 486 ($8.32) price target on the stock. N+1 Singer’s target price would suggest a potential downside of 22.36% from the stock’s previous close.

BTG has been the subject of a number of other recent research reports. Analysts at Panmure Gordon reiterated a “buy” rating on shares of BTG plc in a research note on Wednesday. They now have a GBX 670 ($11.47) price target on the stock. Separately, analysts at FinnCap reiterated a “sell” rating on shares of BTG plc in a research note on Wednesday. They now have a GBX 345 ($5.91) price target on the stock. Finally, analysts at Investec raised their price target on shares of BTG plc from GBX 723 ($12.38) to GBX 728 ($12.46) in a research note on Wednesday, July 2nd. They now have a “buy” rating on the stock. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of GBX 536.88 ($9.19).

Shares of BTG plc (LON:BTG) traded up 0.08% on Wednesday, hitting GBX 626.00. The stock had a trading volume of 444,528 shares. BTG plc has a 52 week low of GBX 363.00 and a 52 week high of GBX 665.00. The stock’s 50-day moving average is GBX 618.5 and its 200-day moving average is GBX 581.8. The company’s market cap is £2.259 billion.

BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.